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Abstract
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the most common and most heterogeneous type of non-
Hodgkin lymphoma. With current therapeutic modalities, 30%–40% of DLBCL cases still experience recurrence. The 
discovery of CD30 expression in DLBCL in several studies has opened up alternative opportunities for new target 
therapies. 
AIM: This cross-sectional study aimed to determine CD30 expression in DLBCL and its difference in expression in 
germinal center B-cell such as (GCB) and non-GCB subtypes. 
METHODS: The sample consisted of 25 GCB and 25 non-GCB cases based on immunohistochemical examination 
performed at Cipto Mangunkusumo Hospital from 2014 to 2017. CD30 staining was carried out and assessed using 
tumor cells percentage with positive cutoff values of >0%, >10%, and >20%.
RESULTS: Positive CD30 expression was obtained in 8 (16%), 4 (8%), and 3 (6%), out of 50 DLBCL cases with 
positive cutoff values of >0%, >10%, and >20%, respectively. We performed Fisher’s exact test to determine CD30 
expression in the GCB and non-GCB subtypes and found no significant difference with p > 0.05.
CONCLUSION: Our study found no significant difference between CD30 expression in the GCB and non-GCB 
subtypes of DLBCL.
Introduction
Lymphoma is a primary malignancy in the lymph 
nodes and lymphoid tissue. Based on its histological type, 
lymphoma is divided into two major groups, non-Hodgkin 
Lymphoma (NHL) and HL [1]. NHL can originate from B 
lymphocytes, T lymphocytes, and NK cells [2]. According 
to the WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues, there are 57 entities categorized 
as NHL, and the most common is diffuse large B-cell 
lymphoma (DLBCL) [3]. The prevalence of DLBCL is 
25–30% in developed countries and even higher in 
developing countries (42.5%) [3], [4]. Data from the Division 
of Hematolymphoid and Bone Marrow, Department of 
Anatomical Pathology, Faculty of Medicine Universitas 
Indonesia – Cipto Mangunkusumo National General 
Hospital recorded DLBCL as the most common type of 
lymphoma (66.34%) of all lymphomas.
DLBCL is the most heterogeneous type of 
NHL. According to the WHO Classification of Tumors of 
Hematopoietic and Lymphoid Tissues, it is categorized 
into different morphological variants, molecular 
subtypes, and distinct disease entities [3]. Based on 
gene-expression profiling (GEP), DLBCL is classified 
into germinal-center B cell-like (GCB), activated B-cell 
(ABC), and type 3 subtypes. The GCB subtype has 
better survival than ABC. The type 3 subtype is very 
heterogeneous and cannot be classified into existing 
groups but has a poor prognosis such as ABC. GEP 
is not practical for daily use, so immunohistochemistry 
(IHC) is used with a substitute algorithm to classify GCB 
and non-GCB subtypes [5].
DLBCL is more common in older people 
with a median age in the seventh decade and occurs 
more often in men. It is generally accompanied by 
rapid enlargement of lymph nodes or extranodal 
masses [3]. These lymphomas have an aggressive 
nature with a survival of <1 year in patients who do 
not receive therapy [6]. The addition of rituximab to 
standard cyclophosphamide, adriamycin, vincristine, 
and prednisone (CHOP) therapy improves the overall 
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survival (OS) of DLBCL patients. However, one-third of 
patients still experience recurrence after therapy [7].
Even though DLBCL has been classified, the 
groups are still heterogeneous. For example, in the GCB 
subtype, which generally has a good prognosis, MYC/BCL2 
double-hit B cell lymphoma can be found, which possesses 
a very aggressive clinical temperament [7], [8]. Many 
studies have been carried out to obtain other indicators/
biomarkers that can help classify DLBCL more specifically 
to provide prognostic clues and open up opportunities for 
new therapeutic approaches [7].
The discovery of CD30 expression in DLBCL 
in several studies has opened alternative opportunities 
for new therapeutic targets. CD30 is a member of 
tumor necrosis factor receptor superfamily, originally 
known as the cell surface marker of Reed-Sternberg 
and Hodgkin cells in classic HL (CHL). These 
receptors are also expressed by several T cells and B 
cells in NHL such as anaplastic large cell lymphoma 
(ALCL), primary cutaneous CD30+ T-cell lymphoma, 
lymphoproliferative disorders, and primary mediastinal 
large B-cell lymphoma [7], [9]. CD30 plays a role in 
increasing and maintaining memory T and B cells, 
B cell proliferation, and increasing immunoglobulin 
production [7]. CD30 expression in DLBCL has been 
investigated by several researchers with varying results 
(10–27%) depending on the positive cutoff value used 
(>0–20%) [7], [10], [11], [12], [13]. Research by Xu et al. 
and Wang et al. used more than one cutoff value and 
obtained different statistical test results with the use of 
different cutoff values [11], [13]. CD30 expression can be 
one of the targets for immunotherapy specific to cancer 
cells. Anti-CD30 monoclonal antibody-drug conjugate, 
brentuximab vedotin, has now been approved for the 
use in ALCL and CHL patients with recurrence [7], [14].
To the best of our knowledge, this is the 
first Indonesian study to analyze CD30 expression 
in DLBCL. From the results of the previous studies, 
the prevalence of CD30 expression in DLBCL and its 
differences between the GCB and non-GCB subtypes 
was still varied, as was the positive cutoff values 
used. The role of CD30 expression in DLBCL is also 
still unknown. We hope that further understanding of 
CD30 expression in DLBCL, with specifications in each 
subtype, will improve knowledge about the biological 
behavior of DLBCL and help determine adjustments in 
therapeutic approaches.
Methods
Patients
The target population of the study was the 
DLBCL. The attainable population was all DLBCL 
cases that had gone through immunohistochemical 
examination in Cipto Mangunkusumo National General 
Hospital from January 2014 to December 2017. The 
selection of samples was done by a consecutive 
sampling of cases that met the inclusion and exclusion 
criteria. The inclusion criteria were DLBCL cases on 
which IHC staining of CD20, CD10, Bcl-6, and MUM1 
had been performed for determination of GCB and 
non-GCB subtypes. Exclusion criteria were cases with 
paraffin blocks that were not found or inadequate and 
DLBCL cases originating from the mediastinum or 
accompanied by mediastinal masses. A sample of 50 
DLBCL cases was obtained, consist of 25 GCB and 25 
non-GCB cases. Approval for the study was granted 
by the Ethics Committee of the Faculty of Medicine, 
University of Indonesia (0960/UN2.F1/ETIK/2018).
IHC staining of CD30
CD30 staining was done using a concentration 
ratio of 1:100. Preparations were heated on a slide 
warmer for 30 min at 60°C. The preparations were 
then deparaffinized with xylol (3×3 min) followed by 
rehydration with decreasing alcohol concentrations 
(ethanol, 96% alcohol, and 70% alcohol, 3 min each) 
and washed with running water for 2 min. Antigen 
retrieval procedure was done using a Tris EDTA buffer, 
pH 9.0, within a decloaking chamber at 96°C for 10 min, 
then cooled and washed with phosphate buffered 
saline (PBS) at pH 7.4 for 2 min. The tissue was then 
marked with a Pap-pen. Endogenous peroxidase 
blocking was carried out for 10 min, followed by a 
2-time washing with pH 7.4 PBS. Background blocking 
was performed for 10 min and washed with pH 7.4 
PBS. Preparations were then incubated with CD30 
primary antibodies (Ki-1 Antigen); Dako clone Ber-H2 
code M0751, for 30 min and washed with pH 7.4 PBS 
4 times, continued by incubation with Novolink polymer 
secondary antibodies for 30 min and washed with pH 
7.4 PBS 3 times. Preparations were incubated with a 
mixture of 1 ml diaminobenzidine tetrahydrochloride 
(DAB) substrate (high contrast) and 1 drop (50 μl) of 
DAB chromogen for 30 s and washed with running 
water for 5 min. Counterstain with Mayer hematoxylin 
for 1 min was performed, and the preparation was 
washed with running water for 5 min. Bluing was carried 
out using lithium carbonate for 10 s and washed with 
running water for 5 min. Dehydration with increasing 
alcohol concentrations (70% alcohol, 96% alcohol, and 
ethanol) followed. The clearing was done using xylol I, 
II, and III, 3 min each. Negative and positive controls 
were included every time staining was performed. The 
positive control for CD30 came from an ALCL case.
Assessment of CD30 expression in 
staining
CD30 expression will show as staining on 
the membrane and/or paranuclear Golgi dots [3], [11]. 
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The assessment was carried out by identifying tumor 
areas that were well-stained, followed by taking several 
photographs in the areas where most stains were 
found. Preparations were assessed with ×400 using 
a Leica ICC50 HD microscope until 500 tumor cells 
were obtained. Photographs were then processed 
using ImageJ®, and the identified cells were calculated 
using a cell counter. We counted both tumor cells 
that expressed CD30 and those that did not. CD30 
expression was assessed in percentage and was 
categorized as positive if it fell above the cutoff values 
of >0%, >10%, or >20%.
Statistical analysis
Data processing was done using SPSS version 
20.0. Statistical analysis used a comparative hypothesis 
test to determine differences in CD30 expression 
between GCB and non-GCB DLBCL subtypes using 
Fisher’s exact test. p < 0.05 was considered statistically 
significant.
Results
Demographic characteristics
Out of 50 subjects, DLBCL was found to occur 
more often at the age of ≤60 years (64%) with an age 
range of 13–83 years, with a median age of 56 years 
and a man-to-woman ratio of 1.2:1. The most common 
tumor sites are extranodal areas (86%) such as the 
tonsils, eyes, nasopharynx, and the sinonasal area 
(Table 1).
Weak, moderate, and strong positive stains were 
categorized as positive. The cutoff values used to 
determine positivity were >0%, >10%, and >20% of 
tumor cells showing positive CD30 staining, according 
to existing literature [7], [10], [11], [12], [13].
Figure 2: Positive control of CD30 staining and positive CD30 
expression using a cutoff value of >20%. (a) Positive control using 
anaplastic large cell lymphoma, (b) non-germinal center B-cell like 
(GCB) diffuse large B-cell lymphoma (DLBCL) with a positive value of 
97.4%, (c) non-GCB DLBCL with a positive value of 62.6% (d) GCB 
DLBCL with a positive value of 29.4% (×400)
a b
c d
The use of the >20% cutoff value obtained 
positive CD30 expression in three (6%) out of 50 cases, 
classified into two non-GCB cases, and one GCB case. 
Morphological variation showed two cases with a 
centroblastic variant and one case with an anaplastic 
variant (Figure 2).
The use of the >10% cutoff value resulted in 
the presence of positive CD30 expression in 4 (8%) out 
of 50 cases, classified into three non-GCB cases, and 
one GCB case. Two cases had a centroblastic variant, 
one case an anaplastic variant, and another case an 
immunoblastic variant (Figure 3)
Table 1: Demographic characteristics of study subjects
Variable GCB subtype 
(n=25)
Non-GCB subtype 
(n=25)
Total (n=50) Percentage
Age
≤60 20 12 32 64
>60 5 13 18 36
Sex
Male 18 9 27 54
Female 7 16 23 46
Tumor site
Nodal 5 2 7 14
Extranodal 20 23 43 86
GCB: Germinal center B-cell like.
The most common morphological variant found 
in the sample was the centroblastic variant (92%). The 
immunoblastic variant was found in three cases (6%), and 
one case was found with an anaplastic variant (Figure 1).
 CD30 expression
CD30 expression was assessed as the 
percentage of tumor cells that were stained positive 
on the membrane and/or perinuclear dots. The positive 
control was obtained from an ALCL case (Figure 2). 
Figure 1: Morphological variants of diffuse large B-cell lymphoma. 
(a and b) Centroblastic variant, (c) immunoblastic variant, (d) 
anaplastic variant (×400)
a b
c d
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A cutoff value of >0% yielded positive CD30 
expression in 8 (16%) out of 50 cases, classified 
into five non-GCB cases, and three GCB cases. The 
morphological variation included six cases with a 
centroblastic variant, one case with an anaplastic 
variant, and one case with an immunoblastic variant 
(Figure 4).
results (CD10, Bcl-6, and MUM1) using all cutoff values 
(Table 2).
Discussion
DLBCL occurs in 25–35% of all adult NHLs 
in developed countries and 42.5% in developing 
countries [3], [4]. Its incidence increases by 3%–4% 
every year [15]. DLBCL is commonly found in old age 
with a median age in the seventh decade, although 
it can also have its onset in childhood and early 
adulthood [3], [16]. This study involved subjects with 
an age range of 13–83 years with a median of 56 
years. The median age is younger compared to several 
studies in Western countries with a median age of 
60–64 years, but quite similar with studies by Hao et al. 
and Gong et al. in China with a median age of 49 and 59 
years [7], [11], [12], [13]. Our study found that DLBCL 
was more prevalent at ≤60 years (64%), as similarly 
found by Chen et al. (75% at <60 years of age) [17].
Our study also found a higher DLBCL incidence 
in men with a ratio of 1.2:1 compared to women. This is in 
accordance with the existing literature, which expressed 
similar ratios ranging from 1.4:1 to 1.9:1 [7], [11], [12], 
[18]. Forty percent of DLBCL cases are located in 
extranodal sites [3], while this study found that 86% of 
its DLBCL cases were located in extranodal sites. This 
could be due to the lack of clinical data that rendered it 
difficult to know nodal involvement in this study.
The addition of rituximab to CHOP standard 
therapy has improved the OS of DLBCL patients; 
however, one-third of DLBCL patients still experience 
recurrence or resistance after therapy [7]. CD30 
expression found in DLBCL has opened opportunities 
for new targeted therapy approaches. CD30 expression 
in DLBCL in several studies showed varied results 
(10–27%) depending on the positive cutoff value used 
(>0–20%) [7], [10], [11], [12], [13]. In a study by Xu 
et al., two cutoff values were used (>0% and >20%), 
and different statistical test results were obtained 
between the two cutoff values [13]. Wang et al. used 
three different cutoff values (>0%, >20%, and >40%) 
and also obtained different statistical test results. 
Therefore, in this study, three cutoff values were 
used. The cutoff values used were taken from existing 
literature [7], [10], [11], [12], [13].
This study assessed CD30 expression 
using IHC staining. A positive result is indicated by 
tumor cell membranes and/or paranuclear Golgi dots 
staining [3], [11]. The results showed that DLBCL 
expressed CD30 in 16%, 8%, and 6% of the 50 cases 
examined using positive cutoff values of >0%, >10%, 
and >20%, respectively. Previous research using a 
cutoff value of >20% received CD30 expression results 
of 12–22% [13], [18]. Salas et al. used a cutoff value of 
Figure 3: Positive CD30 expression using a cutoff value of >10%. 
Non-germinal center B-cell like diffuse large B-cell lymphoma with a 
positive value of 16% (×400)
Fisher’s exact test revealed no significant 
difference between CD30 expression in GCB DLBCL 
and non-GCB DLBCL, with p > 0.05 using all cutoff 
values. Statistical tests were also conducted to see 
differences in CD30 expression in GCB and non-GCB 
subtypes when associated with age, sex, tumor site, 
and results of IHC staining (CD10, Bcl-6, and MUM1). 
Significant differences in CD30 expression were found 
in sex variables using the >10% cutoff value. There 
were no significant differences in CD30 expression 
when associated with age, tumor site, and IHC staining 
Figure 4: Positive CD30 expression using a cutoff value of >0%. (a) 
Non-germinal center B-cell like (GCB) diffuse large B-cell lymphoma 
(DLBCL) with a positive value of 6.6%, (b) GCB DLBCL with a 
positive value of 6%, (c) GCB DLBCL with a positive value of 3.4%, 
(d) non-GCB DLBCL with a positive value of 3% (×400)
a b
c d
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>10% and obtained a 27% result [10]. The use of a >0% 
cutoff value obtained results of 10–41% [11], [13]. These 
varying results might be due to several confounding 
variables such as age, sex, and therapy. In a study that 
found positive CD30 expression in 41% of its subjects, 
primary antibodies with a different clone were used 
(JCM182 Leica) [18].
Fisher’s exact test was performed to assess 
the difference between CD30 expression in GCB 
and non-GCB subtypes using positive cutoff values 
of >0%, >10%, and >20%. All cutoff values yielded 
no statistically significant difference in the proportion 
of CD30 expression. Wang et al. and Zuluaga et al. 
found that CD30 was more likely to be expressed in the 
non-GCB subtype, although no statistical significance 
was found [18], [19]. A study by Salas et al. found 
a significant difference in the proportion of CD30 
expression between GCB and non-GCB subtypes, 
with predominance in non-GCB subtypes [10]. Their 
study used a larger sample size. Hao et al. also 
found a significant difference in the proportion of 
CD30 expression between the two subtypes with the 
predominance of non-GCB subtypes. Their study used 
primary antibodies (clone: EP154) [12]. These varying 
results were likely to be caused by differences in sample 
size, antibody clones, and heterogeneity of patients.
Zuluaga et al. found that in cases with positive 
BCL2 staining, CD30 expression was found 3.9 times 
higher in the non-GCB subtype than in the GCB subtype. 
They also found that the frequency of positive CD30 
expression in DLBCL with positive BCL2 staining was 
higher than the overall CD30 expression frequency in the 
study. BCL2 seems to play a role in CD30 expression, 
where CD30 is expressed in a greater proportion in the 
non-GCB subtype and younger ages if BCL2 is also 
expressed. This interaction is associated with the NF-kB 
transcription factor pathway [19]. Gong et al. obtained 
a positive relationship between CD30 expression and 
BCL2 rearrangement and a negative relationship with 
BCL2 protein expression in the non-GCB subtype. In 
their study, CD30 expression and MYC rearrangement 
were also found to be mutually exclusive [11]. Studies 
conducted by Zaluaga et al. and Gong et al. showed that 
the role of CD30 expression in DLBCL was also influenced 
by several other things. Therefore, further research is 
needed to understand the link between CD30 expression 
in DLBCL and expressions of BCL2 and MYC.
The proportion of CD30 expression is not 
significantly different when associated with age and 
tumor site using all three cutoff values. The studies 
by Wang et al. and Hao et al. also did not obtain any 
significant difference when associated with age [12], [18]. 
In this study, there was a difference in the proportion of 
CD30 expression when associated with sex (p = 0.038). 
Using a cutoff value of >10%, CD30 expression was 
found to be more pronounced in females. The results 
were however not significant when using >0% and 
>20% cutoff values (p = 0.444 and p = 0.090). CD30 
expression was not significantly different between IHC 
staining results of CD10, Bcl-6, and MUM1.
Gong et al. found that CD30 expression was 
more commonly found in cases with centroblastic and 
anaplastic variants [11]. Similarly, we found that the 
largest number of CD30-positive preparations was of 
the centroblastic variant. In one case with an anaplastic 
variant, CD30 expression was also obtained.
Based on our results, it was found that 16% of 
DLBCL cases had the potential to get anti-CD30 target 
therapy. The antibody-drug conjugate brentuximab 
vedotin (SGN-35) which combines monoclonal 
anti-CD30 antibodies with antitubulin agent monomethyl 
auristatin E can be a therapeutic choice for CD30-
positive DLBCL cases. This therapeutic modality is 
very promising due to the limited expression of CD30 in 
only some T cells and B cells in the parafollicular area 
in healthy individuals, making it more selective [19]. 
Brentuximab vedotin has gone through a second-phase 
clinical trial for CD30-positive DLBCL patients who 
experienced recurrence, and results have shown that 
40% of patients achieved a clinical response and 17% 
Table 2: Association between CD30 expression and DLBCL subtype, demographic characteristics, and immunohistochemical 
staining (CD10, Bcl-6, and MUM1)
Variable >0% cutoff >10% cutoff >20% cutoff
CD30+ (n=8) CD30− (n=42) p-value CD30+ (n=4) CD30− (n=46) p-value CD30+ (n=3) CD30− (n=47) p-value
Subtype 0.702 0.609 1.000
GCB 3 22 1 24 1 24
Non-GCB 5 20 3 22 2 23
Age 0.694 0.283 0.544
≤60 6 26 0 18 0 18
>60 2 16 4 28 3 29
Sex 0.444 0.038 0.090
Male 3 24 0 27 0 27
Female 5 18 4 19 3 20
Tumor site 1.000 0.464 0.370
Nodal 1 6 1 6 1 6
Extranodal 7 36 3 40 2 41
CD10 0.702 0.609 1.000
Positive 3 22 1 24 1 24
Negative 5 20 3 22 2 23
Bcl-6 0.413 1.000 1.000
Positive 5 32 3 34 2 35
Negative 3 10 1 12 1 12
MUM1 1.000 1.000 1.000
Positive 7 37 4 40 3 41
Negative 1 5 0 6 0 6
DLBCL: Diffuse large B-cell lymphoma.
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achieved full remission. However, it was said that no 
correlation was found between the average successes 
of therapeutic responses with CD30 expression levels, 
even though all of the included patients had CD30 
expression [20]. These results indicate that the use of a 
cutoff value of >0% in daily clinical practice can ensure 
that more patients benefit from the targeted therapy.
Conclusion
GCB and non-GCB subtypes of DLBCL did not 
have any significant difference in CD30 expression.
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